



Docket No. ORT-1417

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : FOURIE et al

Serial No. : 10/050,200

Art Unit: 1646

Filed : January 18, 2002

Examiner:

For : AGGRECANASE-1 AND 2 PEPTIDE SUBSTRATES AND METHODS

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, Washington, D.C. 20231 on

June 14, 2002

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)



(Signature)

June 14, 2002

(Date of Signature)

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

Applicant(s) reserve(s) the right to establish the  
patentability of the claimed invention over any of the  
information provided herewith, and/or to prove that this  
information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached);  
or

☐ Please charge Deposit Account No. 10-0750/ /  
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);  
or  
☐ Please charge Deposit Account No. 10-0750/ /  
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1417/MHM. This form is submitted in triplicate.

Respectfully submitted,

  
Myra H. McCormack  
Reg. No. 36,602  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
DATED: June 14, 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<b>Application Number</b>	10/050,200
<b>Filing Date</b>	January 18, 2002
<b>First Named Inventor</b>	FOURIE, et. al.
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	ORT-1417

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10,050,200
Filing Date	January 18, 2002
First Named Inventor	FOURIE, et. al.
Group Art Unit	1846
Examiner Name	
Attorney Docket Number	ORT-1417

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ABBASZADE, I., et. al., "Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family", The Journal of Biological Chemistry, 1999 Vol 274(33):23443-23450.	
		BAILEY, S., et al., "Selective Inhibition of Low Affinity IgE Receptor (CD23) Processing: P1' Bicydomethyl Substituents," Bioorganic & Medicinal Chemistry Letters 1999 9:3165-3170.	
		CATERSON, B., et. al., "Mechanisms involved in cartilage proteoglycan catabolism," Matrix Biology 2000 19:333-344.	
		CHEN, J., et. al., "Design, Synthesis, Activity, And Structure Of A Novel Class Of Matrix Metalloproteinase Inhibitors Containing A Heterocyclic P2'-P3' Amide Bond Isostere," Bioorganic & Medicinal Chemistry Letters, 1996 Vol 6(13):1601-1606	
		HORBER, C., et. al., "Truncation of the amino-terminus of the recombinant aggrecan rAgg1(mut) leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions," Matrix Biology 2000 19:533-543.	
		LOHMANDER, L. S., et al., "The Structure of Aggrecan Fragments in Human Synovial Fluid," Arthritis & Rheumatism, 1993 36(9):1214-1222	
		PRATTA, M., et. al., "Age-related Changes in Aggrecan Glycosylation Affect Cleavage by Aggrecanase," Journal of Biological Chemistry, 2000 Vol. 275(50):39096-39102.	
		PRIMAKOFF, P., and MYLES, D. G., "The Adam gene family surface proteins with adhesion and protease activity," Trends Genet 2000 16(2):83-87	
		ROGHANI, M., et. al., "Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity," Journal of Biological Chemistry, 1999 Vol 274(6):3531-3540.	
		SANDY, J.D., et. al., "The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1," Biochemistry Journal 2000 351:161-166	
		TANG, B. L., and Hong, W., "ADAMTS: A novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats," FEBS Letters 445:223-225 1999	
		TORTORELLA, M. D., et. al., "Sites of Aggrecan Cleavage by Recombinant Human Aggrecanase-1 (ADAMTS-4)," Journal of Biological Chemistry 2000 Vol. 275(24):18566-18573.	
		TORTORELLA, M. D., et. al., "Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of Proteins," 1999 Vol 284:1664-1666	
		Medline 98403880, 1998	
		Medline 99367476, 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.